Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial
Dummer, R. Long, G. V. Tawbi, H. A. Flaherty, K. Ascierto, P. A. Nathan, P. D. Rutkowski, P. Leonov, O. Mandala, M. Lorigan, Paul C
Dummer, R.
Long, G. V.
Tawbi, H. A.
Flaherty, K.
Ascierto, P. A.
Nathan, P. D.
Rutkowski, P.
Leonov, O.
Mandala, M.
Lorigan, Paul C
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Dummer R, Long GV, Tawbi HA, Flaherty K, Ascierto PA, Nathan PD, et al. Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302346.